Inventor · disambiguated record
David Glass
Also filed as: GLASS DAVID · GLASS DAVID J · GLASS DAVID JONATHAN
44 granted patents·37 pending applications·562 citations·filing 1994–2025
98Inventor score
Top patents by PatentIndex Score
81 records- 0197US10174095B2Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptorNOVARTIS AG·Filed 2015·Granted Jan 8, 2019·41 cites·50 claims
- 0297US9815901B2Treatment of cancer using a CD123 chimeric antigen receptorBROGDON JENNIFER·Filed 2015·Granted Nov 14, 2017·94 cites·40 claims
- 0396US10004803B2Low, immune enhancing, dose mtor inhibitors and uses thereofNOVARTIS AG·Filed 2016·Granted Jun 26, 2018·13 cites·11 claims
- 0495US11084880B2Anti-BCMA chimeric antigen receptorNOVARTIS AG·Filed 2018·Granted Aug 10, 2021·15 cites·24 claims
- 0595US10357514B2Treatment of cancer using anti-CD19 Chimeric Antigen ReceptorUNIV PENNSYLVANIA·Filed 2015·Granted Jul 23, 2019·18 cites·45 claims
- 0695US10286069B2Low, immune enhancing, dose MTOR inhibitors and uses thereofNOVARTIS AG·Filed 2018·Granted May 14, 2019·8 cites·11 claims
- 0795US8932589B2Methods and compositions using Kloto-FGF23 fusion polypeptidesGLASS DAVID·Filed 2013·Granted Jan 13, 2015·39 cites·17 claims
- 0895US8481031B2Methods and compositions using Klotho-FGF fusion polypeptidesGLASS DAVID·Filed 2009·Granted Jul 9, 2013·43 cites·21 claims
- 0995US8420088B2Methods and compositions using FGF23 fusion polypeptidesGLASS DAVID·Filed 2010·Granted Apr 16, 2013·42 cites·18 claims
- 1094US10287354B2Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2014·Granted May 14, 2019·29 cites·63 claims
- 1193US7355018B2Modified IGF1 polypeptides with increased stability and potencyREGENERON PHARMA·Filed 2004·Granted Apr 8, 2008·42 cites·4 claims
- 1292US7396918B2IGF-I fusion polypeptides and therapeutic uses thereofREGENERON PHARMA·Filed 2006·Granted Jul 8, 2008·14 cites·9 claims
- 1391US10774388B2Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereofNOVARTIS AG·Filed 2015·Granted Sep 15, 2020·7 cites·31 claims
- 1491US8158581B2IGF-1 fusion polypeptides and therapeutic uses thereofGLASS DAVID J·Filed 2010·Granted Apr 17, 2012·15 cites·10 claims
- 1590US7837999B2Method of increasing muscle mass with IGF-1 fusion polypeptidesREGENERON PHARMA·Filed 2008·Granted Nov 23, 2010·11 cites·7 claims
- 1690US7521211B2IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereofREGENERON PHARMA·Filed 2006·Granted Apr 21, 2009·12 cites·7 claims
- 1789US6852838B2Tyrosine kinase receptors and ligandsREGENERON PHARMA·Filed 2001·Granted Feb 8, 2005·15 cites·3 claims
- 1888US12091424B2Rapamycin derivativesNOVARTIS AG·Filed 2021·Granted Sep 17, 2024·1 cites·23 claims
- 1987US8445434B2IGF-1 fusion polypeptides and therapeutic uses thereofGLASS DAVID J·Filed 2012·Granted May 21, 2013·9 cites·6 claims
- 2087US7632503B2Method of treating a muscle-related condition with modified IGF1 polypeptidesREGENERON PHARMA·Filed 2008·Granted Dec 15, 2009·7 cites·2 claims
- 2185US10568947B2Treatment of cancer using a CLL-1 chimeric antigen receptorNOVARTIS AG·Filed 2015·Granted Feb 25, 2020·6 cites·38 claims
- 2284US10982000B2Methods for treating and/or reducing the likelihood of heart failure by administering anti-activin receptor type II (anti-ActRII) antibodyNOVARTIS AG·Filed 2018·Granted Apr 20, 2021·2 cites·6 claims
- 2384US7781404B2IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereofREGENERON PHARMA·Filed 2009·Granted Aug 24, 2010·5 cites·8 claims
- 2483US11578130B2Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2018·Granted Feb 14, 2023·1 cites·30 claims
- 2583US10703819B2Treatment of cancer using a CD123 chimeric antigen receptorNOVARTIS AG·Filed 2017·Granted Jul 7, 2020·1 cites·33 claims
- 2682US8343918B2Stabilized insulin-like growth factor polypeptidesNOVARTIS AG·Filed 2007·Granted Jan 1, 2013·5 cites·16 claims
- 2780US2025223297A1Novel rapamycin derivativesNOVARTIS AG·Filed 2024·Application pending·0 cites
- 2879US10800793B2Rapamycin derivativesNOVARTIS AG·Filed 2018·Granted Oct 13, 2020·1 cites·11 claims
- 2979US2023220090A1Treatment of cancer using a cd123 chimeric antigen receptorNOVARTIS AG·Filed 2022·Application pending·0 cites
- 3077US9475857B2Methods and compositions using a Klotho-FGF23 fusion polypeptideGLASS DAVID·Filed 2014·Granted Oct 25, 2016·2 cites·17 claims
- 3176US2024158514A1Methods for preventing and treating heart diseaseNOVARTIS AG·Filed 2023·Application pending·0 cites
- 3275US9458209B2Methods and compositions using Klotho-FGF fusion polypeptidesNOVARTIS AG·Filed 2013·Granted Oct 4, 2016·2 cites·11 claims
- 3372US2020054742A1Low, immune enhancing, dose mtor inhibitors and uses thereofNOVARTIS AG·Filed 2019·Application pending·0 cites
- 3472US2015140036A1Low, immune enhancing, dose mtor inhibitors and uses thereofMANNICK JOAN·Filed 2014·Application pending·0 cites
- 3572US2023026049A1Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2022·Application pending·0 cites
- 3671US9365651B2Method for treating metabolic disorders by administration of an anti-ActRIIB antibodyFEIGE JEROME·Filed 2012·Granted Jun 14, 2016·4 cites·10 claims
- 3770US12214037B2Treatment of cancer using humanized anti-BCMA chimeric antigen receptorUNIV PENNSYLVANIA·Filed 2021·Granted Feb 4, 2025·0 cites·16 claims
- 3870US11591404B2Treatment of cancer using a CD123 chimeric antigen receptorNOVARTIS AG·Filed 2020·Granted Feb 28, 2023·0 cites·33 claims
- 3970US2025154487A1Engineered alpha klotho polypeptides and uses thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4070US2023052970A1Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptorNOVARTIS AG·Filed 2022·Application pending·0 cites
- 4169US8722621B2Stabilized insulin-like growth factor polypeptidesNOVARTIS AG·Filed 2012·Granted May 13, 2014·1 cites·24 claims
- 4268US2024360153A1Selective rapamycin analogs and uses thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4367US2020392159A1Novel rapamycin derivativesNOVARTIS AG·Filed 2020·Application pending·0 cites
- 4465US11834508B2Method of treating structural and/or functional cardiac abnormalities by administering an anti-ActRII receptor antibodyNOVARTIS AG·Filed 2021·Granted Dec 5, 2023·0 cites·10 claims
- 4565US2020215171A1Treatment of cancer using a cll-1 chimeric antigen receptorNOVARTIS AG·Filed 2019·Application pending·0 cites
- 4664US2020339651A1Methods for b cell preconditioning in car therapyNOVARTIS AG·Filed 2019·Application pending·0 cites
- 4762US6143714AMethods of using hepatocyte growth factor to promote survival, growth and differentiation of motor neuronsREGENERON PHARMA·Filed 1997·Granted Nov 7, 2000·16 cites·4 claims
- 4862US2019388471A1Treatment of cancer using anti-cd19 chimeric antigen receptorNOVARTIS AG·Filed 2019·Application pending·0 cites
- 4962US2021172020A1Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereofNOVARTIS AG·Filed 2020·Application pending·0 cites
- 5059US5814478ATyrosine kinase receptors and ligandsREGENERON PHARMA·Filed 1996·Granted Sep 29, 1998·20 cites·21 claims
Showing the top 50 of 81 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →